Skip to content
TrialScanner

NCT01808638

Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)

Phase 1/Phase 2CompletedSLNLead

Registry record

Lead sponsor
Silence Therapeutics GmbH
Conditions
Carcinoma, Pancreatic Ductal
Primary completion
Aug 2015Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01808638 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01808638: Atu027 Plus Gemcitabine in... | TrialScanner